Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Amortizatization of Intangibles: 2011-2024

Historic Amortizatization of Intangibles for Heron Therapeutics (HRTX) over the last 14 years, with Dec 2024 value amounting to $2.1 million.

  • Heron Therapeutics' Amortizatization of Intangibles fell 76.06% to $130,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year decrease of 55.22%. This contributed to the annual value of $2.1 million for FY2024, which is 23.23% up from last year.
  • According to the latest figures from FY2024, Heron Therapeutics' Amortizatization of Intangibles is $2.1 million, which was up 23.23% from $1.7 million recorded in FY2023.
  • Heron Therapeutics' Amortizatization of Intangibles' 5-year high stood at $2.1 million during FY2024, with a 5-year trough of $736,000 in FY2022.
  • In the last 3 years, Heron Therapeutics' Amortizatization of Intangibles had a median value of $1.7 million in 2023 and averaged $1.5 million.
  • As far as peak fluctuations go, Heron Therapeutics' Amortizatization of Intangibles plummeted by 61.69% in 2020, and later skyrocketed by 136.28% in 2023.
  • Heron Therapeutics' Amortizatization of Intangibles (Yearly) stood at $1.4 million in 2020, then tumbled by 45.07% to $785,000 in 2021, then fell by 6.24% to $736,000 in 2022, then spiked by 136.28% to $1.7 million in 2023, then grew by 23.23% to $2.1 million in 2024.